Author(s): Schoedel KA, Chen N, Hilliard A, White L, Stott C, et al.
Objective:This study aimed to evaluate the abuse potential and cognitive effects of nabiximols (Sativex, GW Pharma Ltd. Salisbury, UK), an oromucosal spray primarily containing delta‐9‐tetrahydrocannabinol (THC) and cannabidiol (CBD).
Methods:This was a single‐dose, randomized, double‐blind, crossover study comparing nabiximols (4, 8, and 16 consecutive sprays: 10.8, 21.6, and 43.2 mg THC, respectively) with dronabinol 20 and 40 mg (synthetic THC: Marinol, Solvay Pharmaceuticals, Brussels, Belgium) and matching placebos in 23 recreational cannabis users. Subjective and cognitive/psychomotor measures were administered over 24 h post‐dose.
Results:Dronabinol was significantly different from placebo on abuse potential measures, thereby confirming study validity. Nabiximols 10.8 mg was not significantly different from placebo on primary measures but was different on some secondary measures. Nabiximols 21.6 mg was significantly greater than placebo on some primary/secondary measures, whereas nabiximols 43.2 mg showed significant effects on most measures. Nabiximols 10.8 mg was significantly lower than dronabinol doses on most measures ( p < 0.05). Dronabinol 20 mg effects were numerically higher than nabiximols 21.6 mg but were statistically significant only for some measures. Dronabinol 40 mg and nabiximols 43.2 mg were generally not statistically different.
Conclusions:Both dronabinol and nabiximols had significant abuse potential compared with placebo at higher doses. Nabiximols showed similar or slightly less abuse potential compared with dronabinol. Therefore, the abuse potential of nabiximols should be no higher than that of dronabinol.
Referred From: https://pubmed.ncbi.nlm.nih.gov/21671456/
Author(s): Rizzo MA, Hadjimichael OC, Preiningerova J, Vollmer TL
Author(s): Beard S, Hunn A, Wight J
Author(s): Shakespeare DT, Boggild M, Young C
Author(s): Russo EB
Author(s): Wade DT, Makela P, Robson P, House H, Bateman C
Author(s): Collin C, Davies P, Mutiboko IK, Ratcliffe S; Sativex Spasticity in MS Study Group
Author(s): Novotna A, Mares J, Ratcliffe S, Novakova I, Zapletalova O, et al
Author(s): Wade DT, Collin C, Stott C, Duncombe P
Author(s): Serpell MG, Notcutt W, Collin C
Author(s): Mechoulam R, Parker LA
Author(s): Bovasso GB
Author(s): Degenhardt L, Hall W, Lynskey M
Author(s): Lynskey MT, Glowinski AL, Todorov AA, Bucholz KK, Madden PA, et al.
Author(s): Dougherty DM, Mathias CW, Dawes MA, Furr RM, Charles N, et al.
Author(s): Achiron A, Chapman J, Magalashvili D, Dolev M, Lavie M, et al.
Author(s): Stott CG, White L, Wright S, Wilbraham D, Guy GW
Author(s): Fischer JS, Rudick RA, Cutter GR, Reingold SC
Author(s): Bohannon RW, Smith MB
Author(s): Endler NS, Rutherford A, Denisoff E
Author(s): Rog DJ, Nurmikko TJ, Friede T, Young CA
Author(s): Collin C, Ehler E, Waberzinek G, Alsindi Z, Davies P et al.
Author(s): Feinstein A
Author(s): Notcutt WG
Author(s): Pandyan AD, Johnson GR, Price CI, Curless RH, Barnes MP et al.
Author(s): Nurmikko TJ, Serpell MG, Hoggart B, Toomey PJ, Morlion BJ et al.